+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Pulse therapy with prospidin and methotrexate: comparative efficacy in rheumatoid arthritis (12-month controlled study)



Pulse therapy with prospidin and methotrexate: comparative efficacy in rheumatoid arthritis (12-month controlled study)



Klinicheskaia Meditsina 76(8): 24-28



Efficiency of pulse-therapy with prospidin (500 mg for 5 days in hospital, 500-1000 mg for a month as maintenance) and methotrexate (30 mg a week i.v. in hospital, 7-10 mg a week as maintenance) was investigated in 93 patients with severe RA. The response to prospidin and methotrexate arose quickly (within 10-14 and 4-5 weeks, respectively) and occurred in 73 and 70% of patients, respectively. Withdrawal of the drug was caused by side effects of methotrexate (19.3%) and resistance to prospidin (23.2%).

(PDF emailed within 1 workday: $29.90)

Accession: 047132511

Download citation: RISBibTeXText

PMID: 9770962


Related references

Pulse methotrexate therapy in rheumatoid arthritis. A controlled prospective roentgenographic study. Annals of Internal Medicine 107(6): 797-801, 1987

Comparative efficacy and safety of TNF-inhibitor plus methotrexate versus oral triple therapy in patients with active rheumatoid arthritis inadequately responding to methotrexate: A meta-analysis of randomized controlled trials. International Journal of Clinical Pharmacology and Therapeutics 56(6): 263-269, 2018

Prospidine versus methotrexate pulse in highly active rheumatoid arthritis: A controlled 6-month clinical trial. Clinical Rheumatology 13(1): 54-59, 1994

Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology 42(12): 1545-1549, 2003

Prospidin a new basic agent for the treatment of rheumatoid arthritis a clinical study of the drug efficacy in controlled and double blind tests. Revmatologiya (3): 36-40, 1985

Pulse therapy with methylprednisolone and cyclophosphamide in systemic juvenile rheumatoid arthritis: the results of an open, parallel, controlled, randomized, 12-month study. Terapevticheskii Arkhiv 64(5): 47-51, 1992

A new basic drug prospidin in the treatment of rheumatoid arthritis. III. Comparative analysis of prospidin and cyclophosphamide. Terapevticheskii Arkhiv 59(4): 76-79, 1987

The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. Journal of Rheumatology 24(11): 2230-2232, 1998

Janus kinase inhibitor baricitinib for rheumatoid arthritis : Randomized, double-blind, placebo- and active-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy (RA-BEAM). Der Internist 58(12): 1341-1344, 2017

Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Annals of the Rheumatic Diseases 68(12): 1898-1901, 2010

A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. Journal of the Formosan Medical Association 103(8): 618-623, 2004

The new basic agent prospidin in the therapy of rheumatoid arthritis. An evaluation of the clinical effectiveness and the mechanism of action of prospidin. Terapevticheskii Arkhiv 58(12): 103-108, 1986

Efficacy of FK506 in rheumatoid arthritis A 6 month, dose-ranging study in RA patients failing methotrexate. Arthritis & Rheumatism 42(9 SUPPL ): S271, Sept, 1999

Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Modern Rheumatology 24(3): 410-418, 2015

Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo-controlled double-blind parallel-group study. Journal of Rheumatology 39(3): 486-495, 2012